Jeffrey A. Baumel

973.639.5904
Fax 973.297.3814
jbaumel@mccarter.com

December 13, 2005

Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, DC 20549

Attn: David Roberts

Re:   American Caresource Holdings, Inc. (the "Company" or the "Registrant")
      File No. 333-122820

Dear Mr. Roberts:

      On behalf of the Registrant, set forth below is the Registrant's response
to the Staff's comment letter dated December 12, 2005 (the "SEC Letter"). Set
forth below is the text of the comments contained in the SEC Letter and the
Company's response thereto. The heading and numbered paragraphs below correspond
to the headings and paragraph numbers in the SEC Letter.

General

1.    On the cover page, you state that 10,091,899 shares are being distributed
      pursuant to this prospectus. However, on page 30 you state that 10,981,899
      shares are being distributed. Please advise us as to the reason for the
      discrepancy or revise as necessary. In addition, please correct the
      typographical error on page 28 that indicates that 10,91,899 shares are
      being distributed.

      The typographical errors appearing on page 28 and 30 (the number in each
      should read 10,091,899) will be corrected in the final prospectus to be
      filed in accordance with Rule 424(b)(3) under the Securities Act of 1933.



Securities and Exchange Commission
December 13, 2005
Page 2


Financial Statements

Notes to Unaudited Condensed Financial Statements for the Period Ended September
30, 2005

Issuance of Warrants, page F-21

2.    We reviewed your response to comment 5. As follow-up to our conference
      call with the Company on December 12, 2005, please tell us your
      consideration of paragraphs 20-21 of EITF 00-19 as it relates to the
      anti-dilution provisions that could potentially adjust the exercise price
      of the warrants issued. In this regard, you should clarify that the
      triggering events noted in the warrant agreements are within the Company's
      control.

      Paragraph 20 of EITF 00-19 notes that ". . . a company must evaluate
      whether a sufficient number of authorized and unissued shares exists at
      the classification assessment date to control settlement by delivering
      shares."

      The following table illustrates, without regard to the anti-dilution
      provisions discussed below, that there are sufficient authorized and
      unissued and uncommitted shares to satisfy warrant settlements under all
      currently outstanding warrants.

         Total common shares authorized                               40,000,000
         Less common shares outstanding                               12,371,309
         Less shares underlying options granted                        1,612,206
                                                                      ----------
         Total shares available to satisfy warrant settlements        26,016,485
                                                                      ==========
         Total warrants outstanding                                    1,737,550
                                                                      ==========

      The warrant agreement referred to by the Staff contains a series of, what
      are intended to be, standard anti-dilution provisions which could affect
      the exercise price and number of warrant shares to be issued upon exercise
      thereof. The provisions provide for the adjustment to the exercise price
      and number of shares issuable upon exercise of the warrants upon the
      occurrence of certain events, including stock splits, rights offerings,
      dividends of non cash assets or indebtedness, and the sale of securities
      by the Company at a price below the exercise price of the warrants. There
      are absolutely no anti-dilution provisions contained in the warrant which
      could be triggered by events or actions that are not under the control of
      the Company.

      For example, none of a stock split, rights offering nor dividend could be
      declared without the affirmative approval of the Board of Directors of the
      Corporation. Also, the price protection anti-dilution provisions only come
      into effect upon the offer and sale of shares by the Company, which also
      cannot occur without the approval of the Board of Directors of the
      Company. The price protection anti-dilution provisions do not apply to and
      are not triggered by mere changes in the market price of the Company's
      shares.



Securities and Exchange Commission
December 13, 2005
Page 3


      All of the triggering events are under the Company's control.

      Paragraph 21 of EITF 00-19 states that "If the number of shares that could
      be required to be delivered to net-share settle the contract is
      indeterminate, a company will be unable to conclude that it has sufficient
      available authorized and unissued shares and, therefore net-share
      settlement is not within the control of the company."

      The number of shares to be issued under the warrant agreements is set
      forth clearly in each warrant agreement, and may only be adjusted upon the
      occurrence of the events set forth in the anti-dilution provisions
      discussed above. Since the anti-dilution provisions can only be triggered
      by a Company action, the Company will know the effect of the anti-dilution
      provisions prior to undertaking the action and may increase authorized
      capital at the same time that any such action is taken. In the unlikely
      event that triggering event results in there being insufficient unissued
      and uncommitted shares, the classification of the warrants would be
      reclassified at that time in accordance with paragraph 10 of EITF00-19.

      Finally, the Company represents that there is currently no agreement or
      arrangement in place or other action anticipated to be taken that would
      result in any adjustment to the warrants under the anti-dilution
      provisions described above.

      We appreciate your prompt response to our filing. If you have any
questions, or if we may be of any assistance, please contact the undersigned at
(973) 622-4444.

Very truly yours,


/s/ Jeffrey A. Baumel

Jeffrey A. Baumel

JAB:an